Patents Examined by Svetlana M Ivanova
  • Methods of treating hepatic encephalopathy
    Patent number: 10335397
    Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Salix Pharmaceuticals, Ltd
    Inventor: William Forbes
  • Agent for treatment of PBC
    Patent number: 10314825
    Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 11, 2019
    Assignee: KOWA COMPANY, LTD.
    Inventors: Mitsumasa Nakamura, Satoshi Kojima, Ryohei Tanigawa
  • Lactam solubility
    Patent number: 10306886
    Abstract: Compositions comprising a lactam and an alcohol. The compositions are suitable for use as anti-microbial, anti-biofilm and bacteriostatic compositions.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: June 4, 2019
    Assignee: CONOPCO INC.
    Inventor: Paul Damien Price
  • Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
    Patent number: 10292995
    Abstract: A method of and composition for treating a patient having Mycobacterium avium complex (MAC), and in one embodiment Mycobacterium avium subspecies paratuberculosis (MAP), causing one or more diseases, an embodiment of the method including administering to the patient an effective amount of one or more antibiotics and administering to the patient an effective amount of ultraviolet blood irradtiation (UVBI) treatments, and an embodiment of the composition including an effective amount of one or more antibiotics and an effective amount of UVBI treated blood of the patient.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 21, 2019
    Inventor: John Todd Kuenstner
  • Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
    Patent number: 10285963
    Abstract: The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 14, 2019
    Inventor: Horacio Astudillo de la Vega
  • Spot-on active substance formulation
    Patent number: 10271553
    Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising an aliphatic cyclic carbonate, an aromatic alcohol, sorbitan monolaurate (Span 20) and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, lice, fleas, ticks, mosquitoes and sand flies in pets such as, in particular, in dogs and ferrets.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: April 30, 2019
    Assignee: Evergreen Animal Health, LLC
    Inventors: Olaf Hansen, Rudy Thoma
  • Nootropic compositions for improving memory performance
    Patent number: 10265304
    Abstract: The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 23, 2019
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Pharmaceutical combination comprising a selective S1P1 receptor agonist
    Patent number: 10245253
    Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: April 2, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Martine Clozel, Luca Piali
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
    Patent number: 10231972
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with 4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: March 19, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Friedhelm Bladt, Manja Friese-Hamim
  • Anaplerotic therapy of huntington disease and other polyglutamine diseases
    Patent number: 10220014
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 5, 2019
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Durr, Fanny Mochel
  • Role of N-2-hydroxy-ethyl-piperazine-N?-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury
    Patent number: 10213425
    Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: February 26, 2019
    Assignee: BESPOKE BIOSCIENCE, LLC
    Inventor: Ivan E. Danhof
  • Oxidized lipids and treatment or prevention of fibrosis
    Patent number: 10206936
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: February 19, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Method for identifying subjects with increased risk of ST-segment elevation myocardial infarction (STEMI) and identifying subjects likely to respond to particular treatments
    Patent number: 10203322
    Abstract: A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 12, 2019
    Assignee: Vanderbilt University
    Inventors: Olivier Boutaud, Elias V. Haddad, Eitan Friedman
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 10195210
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 5, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
    Patent number: 10172873
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 8, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, XUHANG Li
  • Antileishmanial compositions and methods of use
    Patent number: 10174072
    Abstract: In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 8, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Abhay R. Satoskar, James F. Fuchs, Alan Douglas Kinghorn, Li Pan, Claudio M. Lezama-Davila, Eric Bachelder
  • Formulations of an LSD1 inhibitor
    Patent number: 10166221
    Abstract: The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: January 1, 2019
    Assignee: Incyte Corporation
    Inventors: William L. Rocco, Ying Liu, Mei Li, Tanvi Shah, Huifang Wu
  • Pharmaceutical composition containing pyridylaminoacetic acid compound
    Patent number: 10149908
    Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: December 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventor: Yoko Endo
  • Nrf2 regulators
    Patent number: 10144731
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: December 4, 2018
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics, Ltd
    Inventors: Thomas Glanmor Davies, Alison Jo-anne Woolford, Hendrika Maria Gerarda Willems, David Norton, Thomas Daniel Heightman, Jeffrey K. Kerns
  • Methods and compositions for prevention and treatment of cardiac hypertrophy
    Patent number: 10137123
    Abstract: Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel TR-PV1 inhibitor. The methods include treatment of a symptom of cardiac hypertrophy in the subject comprises cardiac remodeling, cardiac fibrosis, apoptosis, hypertension, or heart failure.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: November 27, 2018
    Assignee: University of Hawaii
    Inventor: Alexander Stokes